ABSTRACT
Introduction The Diversion Alert Program (DAP) was established to curb the misuse of drugs and help identify people in need of substance use disorder (SUD) treatment. Law enforcement compiled arrest data into a database accessible by health care providers. The objectives of this investigation were to identify regional and demographic differences in drug use and misuse in Maine.
Methods All arrests (N = 11,234) reported to the DAP from 2013 to 2018 were examined by county, arrestee demographics, and classified into families (opioids, stimulants, sedatives). The Automation of Reports and Consolidated Orders System (ARCOS) tracks the distribution of controlled pharmaceuticals (schedule I-V). Opioids were converted to oral morphine mg equivalents (MME). County and zip-code heat maps were constructed.
Results The counties with the most arrests per capita were Cumberland, Androscoggin, and Penobscot. Opioids were the most common drug class in arrests in all counties except Aroostook, where stimulants were most common. Medical distribution of opioids varied. With the exception of buprenorphine, which doubled, many prescription opioids like hydrocodone, fentanyl, and oxymorphone exhibited large (>50%) reductions. Methadone was the predominant opioid statewide (56.4% of the total MME) although there were sizeable differences (Presque Isle = 8.6%, Bangor = 78.9%) and this is likely impacted by use for SUD treatment. Amphetamine distribution increased by 67.9%. Conclusions: The DAP was useful to prevent information silos and enhance communication between law enforcement and health care providers. Maine’s DAP was a unique system to identify patients in need of additional treatment resources. The increase in prescription stimulants may warrant continued monitoring.
Competing Interest Statement
BJP has osteoarthritis research supported by Pfizer. A member of his household was previously employed by Garlic Acres, a company that produced medical cannabis products. SDN has consulted for Shire. MF and CED were employed by the Diversion Alert Program. The other authors have no disclosures.
Clinical Trial
This is a descriptive study without a trial ID.
Funding Statement
This research was supported by the Fah-Beck Fund for Research and Experimentation and the Health Resource and Services Administration (D34HP31025).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Procedures were approved by the ethics committee of the University of New England.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, psy391{at}gmail.com or bpiper{at}som.geisinger.edu
Data Availability
Arrest data is sensitive. Our data use agreement precludes sharing Diversion Alert data. The Drug Enforcement Administration's ARCOS data is publically available online.
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html